Skip to main content
Clinical Trials/NCT05269537
NCT05269537
Completed
Not Applicable

Changes in Cardiac Output During Cesarean Delivery Under Spinal Anesthesia. A Prospective Observational Study Using Transthoracic Echocardiography

Mansoura University1 site in 1 country60 target enrollmentMarch 12, 2022

Overview

Phase
Not Applicable
Intervention
Transthoracic Echocardiography
Conditions
Anesthesia, Spinal
Sponsor
Mansoura University
Enrollment
60
Locations
1
Primary Endpoint
Changes in cardiac output
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Cardiac output will be measured in healthy parturients undergoing cesarean delivery under spinal anesthesia

Detailed Description

ASA-II women undergoing cesarean delivery under spinal anesthesia will be included. Cardiac output will be measured using transthoracic echocardiography at 4 time points: Baseline, after 10 minutes of intrathecal injection, after delivery, and after 1 hour of intrathecal injection. Spinal anesthesia will be administered with 2.5 ml bupivacaine 0.5% and fentanyl 15 μg.

Registry
clinicaltrials.gov
Start Date
March 12, 2022
End Date
July 2, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamed Mohamed Tawfik

Assistant Professor, Department of Anesthesia and Surgical Critical Care, Mansoura University Hospitals, Mansoura, Egypt

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists physical status II parturients.
  • Full term, singleton pregnancy
  • Elective cesarean delivery under spinal anesthesia

Exclusion Criteria

  • Height \<150 cm
  • Weight \<60 kg
  • Body mass index (BMI) \<18.5 or ≥ 35 kg/m²
  • Women presenting in labor
  • Contraindications to spinal anesthesia: increased intracranial pressure, coagulopathy, or local skin infection
  • Hemoglobin \<10 g/dL
  • Current administration of vasoactive drugs (e.g., salbutamol, thyroxin)
  • Diabetes mellitus, cardiovascular, or renal disease
  • Chronic or pregnancy-induced hypertension
  • Polyhydramnios

Arms & Interventions

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Transthoracic Echocardiography

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Spinal Anesthesia

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Intrathecal Bupivacaine

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Intrathecal Fentanyl

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Crystalloid Coload 1000 mL

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Cesarean Delivery

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Intravenous Ephedrine

Study Group

Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.

Intervention: Oxytocin

Outcomes

Primary Outcomes

Changes in cardiac output

Time Frame: At baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection

Cardiac output measured using transthoracic echocardiography

Secondary Outcomes

  • Number of subjects requiring ephedrine(From intrathecal injection to the end of cesarean delivery)
  • Incidence of severe hypotension(From intrathecal injection to the end of cesarean delivery)
  • Incidence of bradycardia(From intrathecal injection to the end of cesarean delivery)
  • Neonatal Apgar scores(At 1 and 5 minutes after delivery)
  • Changes in heart rate(At baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection)
  • Changes in stroke volume(At baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection)
  • Incidence of hypotension(From intrathecal injection to the end of cesarean delivery)
  • Incidence of nausea and/or vomiting(From intrathecal injection to the end of cesarean delivery)

Study Sites (1)

Loading locations...

Similar Trials